{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,1,16]],"date-time":"2026-01-16T19:56:19Z","timestamp":1768593379195,"version":"3.49.0"},"reference-count":52,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T00:00:00Z","timestamp":1602028800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Oncol."],"DOI":"10.3389\/fonc.2020.579221","type":"journal-article","created":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T05:22:55Z","timestamp":1602048175000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":13,"title":["Comparison and Implications of Mutational Profiles of Myelodysplastic Syndromes, Myeloproliferative Neoplasms, and Myelodysplastic\/Myeloproliferative Neoplasms: A Meta-Analysis"],"prefix":"10.3389","volume":"10","author":[{"given":"Ziqi","family":"Wan","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Bing","family":"Han","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"1965","published-online":{"date-parts":[[2020,10,7]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"425","DOI":"10.1038\/nrc.2017.40","article-title":"Turning the tide in myelodysplastic\/myeloproliferative neoplasms","volume":"17","author":"Deininger","year":"2017","journal-title":"Nat Rev Cancer."},{"key":"B2","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1056\/NEJMoa1103283","article-title":"Somatic SF3B1 mutation in myelodysplasia with ring sideroblasts","volume":"365","author":"Papaemmanuil","year":"2011","journal-title":"N Engl J Med."},{"key":"B3","doi-asserted-by":"publisher","first-page":"387","DOI":"10.1016\/j.ccr.2005.03.023","article-title":"Activating mutation in the tyrosine kinase JAK2 in polycythemia vera, essential thrombocythemia, and myeloid metaplasia with myelofibrosis","volume":"7","author":"Levine","year":"2005","journal-title":"Cancer cell."},{"key":"B4","doi-asserted-by":"publisher","first-page":"2008","DOI":"10.1001\/jama.283.15.2008","article-title":"Meta-analysis of observational studies in epidemiology: a proposal for reporting. Meta-analysis Of Observational Studies in Epidemiology (MOOSE) group","volume":"283","author":"Stroup","year":"2000","journal-title":"JAMA."},{"key":"B5","doi-asserted-by":"publisher","first-page":"937","DOI":"10.1182\/blood-2009-03-209262","article-title":"The 2008 revision of the World Health Organization (WHO) classification of myeloid neoplasms and acute leukemia: rationale and important changes","volume":"114","author":"Vardiman","year":"2009","journal-title":"Blood."},{"key":"B6","doi-asserted-by":"publisher","first-page":"2391","DOI":"10.1182\/blood-2016-03-643544","article-title":"The 2016 revision to the World Health Organization classification of myeloid neoplasms and acute leukemia","volume":"127","author":"Arber","year":"2016","journal-title":"Blood."},{"key":"B7","doi-asserted-by":"publisher","first-page":"1049","DOI":"10.1182\/blood-2018-10-844621","article-title":"Genetics of MDS","volume":"133","author":"Ogawa","year":"2019","journal-title":"Blood."},{"key":"B8","doi-asserted-by":"publisher","first-page":"30","DOI":"10.1002\/gcc.22789","article-title":"Targeted molecular characterization shows differences between primary and secondary myelofibrosis","volume":"59","author":"Courtier","year":"2020","journal-title":"Genes Chromosomes Cancer."},{"key":"B9","doi-asserted-by":"publisher","first-page":"681","DOI":"10.1002\/ajh.24377","article-title":"Epidemiology and clinical relevance of mutations in postpolycythemia vera and postessential thrombocythemia myelofibrosis: a study on 359 patients of the AGIMM group","volume":"91","author":"Rotunno","year":"2016","journal-title":"Am J Hematol."},{"key":"B10","doi-asserted-by":"publisher","first-page":"e244","DOI":"10.3324\/haematol.2014.113159","article-title":"Specific molecular mutation patterns delineate chronic neutrophilic leukemia, atypical chronic myeloid leukemia, and chronic myelomonocytic leukemia","volume":"99","author":"Meggendorfer","year":"2014","journal-title":"Haematologica."},{"key":"B11","doi-asserted-by":"publisher","first-page":"3616","DOI":"10.1182\/blood-2013-08-518886","article-title":"Clinical and biological implications of driver mutations in myelodysplastic syndromes","volume":"122","author":"Papaemmanuil","year":"2013","journal-title":"Blood."},{"key":"B12","doi-asserted-by":"publisher","first-page":"1086","DOI":"10.1182\/blood-2018-10-844670","article-title":"MDS overlap disorders and diagnostic boundaries","volume":"133","author":"Tanaka","year":"2019","journal-title":"Blood."},{"key":"B13","doi-asserted-by":"publisher","first-page":"667","DOI":"10.1182\/blood-2016-10-695940","article-title":"Genetic basis and molecular pathophysiology of classical myeloproliferative neoplasms","volume":"129","author":"Vainchenker","year":"2017","journal-title":"Blood."},{"key":"B14","doi-asserted-by":"publisher","first-page":"204","DOI":"10.1038\/ng.3742","article-title":"Dynamics of clonal evolution in myelodysplastic syndromes","volume":"49","author":"Makishima","year":"2017","journal-title":"Nat Genet."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1096","DOI":"10.1182\/blood-2018-10-844696","article-title":"Treatment of MDS","volume":"133","author":"Platzbecker","year":"2019","journal-title":"Blood."},{"key":"B16","doi-asserted-by":"publisher","first-page":"6239","DOI":"10.1182\/blood-2011-09-377275","article-title":"Clinical significance of SF3B1 mutations in myelodysplastic syndromes and myelodysplastic\/myeloproliferative neoplasms","volume":"118","author":"Malcovati","year":"2011","journal-title":"Blood."},{"key":"B17","doi-asserted-by":"publisher","first-page":"297","DOI":"10.1002\/ajh.24637","article-title":"Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis (RARS-T):2017 update on diagnosis, risk-stratification, and management","volume":"92","author":"Patnaik","year":"2017","journal-title":"Am J Hematol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"178","DOI":"10.1016\/j.leukres.2005.06.015","article-title":"Usefulness and prognostic impact on survival of WHO reclassification in FAB low risk myelodyplastic syndromes","volume":"30","author":"Breccia","year":"2006","journal-title":"Leuk Res."},{"key":"B19","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1111\/cas.14270","article-title":"Mutation status and burden can improve prognostic prediction of patients with lower-risk myelodysplastic syndromes","volume":"111","author":"Jiang","year":"2020","journal-title":"Cancer Sci."},{"key":"B20","doi-asserted-by":"publisher","first-page":"138","DOI":"10.1111\/j.1365-2141.2005.05416.x","article-title":"Gene expression profiling in polycythaemia vera: overexpression of transcription factor NF-E2","volume":"129","author":"Goerttler","year":"2005","journal-title":"Br J Haematol."},{"key":"B21","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1084\/jem.20110540","article-title":"A novel murine model of myeloproliferative disorders generated by overexpression of the transcription factor NF-E2","volume":"209","author":"Kaufmann","year":"2012","journal-title":"J Exp Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"1003","DOI":"10.1084\/jem.20120521","article-title":"MPN patients harbor recurrent truncating mutations in transcription factor NF-E2","volume":"210","author":"Jutzi","year":"2013","journal-title":"J Exp Med."},{"key":"B23","doi-asserted-by":"publisher","first-page":"2065","DOI":"10.1182\/blood-2017-10-810622","article-title":"Epigenetic regulation of NFE2 overexpression in myeloproliferative neoplasms","volume":"131","author":"Peeken","year":"2018","journal-title":"Blood."},{"key":"B24","doi-asserted-by":"publisher","first-page":"905","DOI":"10.1038\/leu.2009.47","article-title":"TET2 mutations and their clinical correlates in polycythemia vera, essential thrombocythemia and myelofibrosis","volume":"23","author":"Tefferi","year":"2009","journal-title":"Leukemia."},{"key":"B25","doi-asserted-by":"publisher","first-page":"dmm035790","DOI":"10.1242\/dmm.035790","article-title":"Disruption of asxl1 results in myeloproliferative neoplasms in zebrafish","volume":"12","author":"Gjini","year":"2019","journal-title":"Dis Models Mechanisms."},{"key":"B26","doi-asserted-by":"publisher","first-page":"447","DOI":"10.1158\/0008-5472.CAN-09-3783","article-title":"Genetic analysis of transforming events that convert chronic myeloproliferative neoplasms to leukemias","volume":"70","author":"Abdel-Wahab","year":"2010","journal-title":"Cancer Res."},{"key":"B27","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1097\/MOH.0000000000000017","article-title":"Pathogenesis and management of acute myeloid leukemia that has evolved from a myeloproliferative neoplasm","volume":"21","author":"Rampal","year":"2014","journal-title":"Curr Opin Hematol."},{"key":"B28","doi-asserted-by":"publisher","first-page":"e366","DOI":"10.1038\/bcj.2015.95","article-title":"Blast transformation and fibrotic progression in polycythemia vera and essential thrombocythemia: a literature review of incidence and risk factors","volume":"5","author":"Cerquozzi","year":"2015","journal-title":"Blood Cancer J."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1083","DOI":"10.1182\/blood-2014-08-550483","article-title":"How I treat juvenile myelomonocytic leukemia","volume":"125","author":"Locatelli","year":"2015","journal-title":"Blood."},{"key":"B30","doi-asserted-by":"publisher","first-page":"1326","DOI":"10.1038\/ng.3400","article-title":"The genomic landscape of juvenile myelomonocytic leukemia","volume":"47","author":"Stieglitz","year":"2015","journal-title":"Nat Genet."},{"key":"B31","doi-asserted-by":"publisher","first-page":"1334","DOI":"10.1038\/ng.3420","article-title":"Juvenile myelomonocytic leukemia displays mutations in components of the RAS pathway and the PRC2 network","volume":"47","author":"Caye","year":"2015","journal-title":"Nat Genet."},{"key":"B32","doi-asserted-by":"publisher","first-page":"1576","DOI":"10.1182\/blood-2017-07-798157","article-title":"Integrated molecular profiling of juvenile myelomonocytic leukemia","volume":"131","author":"Murakami","year":"2018","journal-title":"Blood."},{"key":"B33","doi-asserted-by":"publisher","first-page":"459","DOI":"10.1182\/blood.V93.2.459","article-title":"Myelodysplastic and myeloproliferative disorders of childhood: a study of 167 patients","volume":"93","author":"Luna-Fineman","year":"1999","journal-title":"Blood."},{"key":"B34","doi-asserted-by":"publisher","first-page":"475","DOI":"10.1002\/ajh.25397","article-title":"Refractory anemia with ring sideroblasts (RARS) and RARS with thrombocytosis: \u201c2019 update on diagnosis, risk-stratification, and management","volume":"94","author":"Patnaik","year":"2019"},{"key":"B35","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1002\/ajh.24332","article-title":"Predictors of survival in refractory anemia with ring sideroblasts and thrombocytosis (RARS-T) and the role of next-generation sequencing","volume":"91","author":"Patnaik","year":"2016","journal-title":"Am J Hematol."},{"key":"B36","doi-asserted-by":"publisher","first-page":"1060","DOI":"10.1182\/blood-2018-11-844688","article-title":"Juvenile myelomonocytic leukemia: who's the driver at the wheel?","volume":"133","author":"Niemeyer","year":"2019","journal-title":"Blood."},{"key":"B37","doi-asserted-by":"publisher","first-page":"129","DOI":"10.1080\/17474086.2018.1421937","article-title":"Novel approaches to diagnosis and treatment of Juvenile myelomonocytic leukemia","volume":"11","author":"Locatelli","year":"2018","journal-title":"Expert Rev Hematol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"233","DOI":"10.1182\/blood-2015-03-633537","article-title":"SF3B1 mutation identifies a distinct subset of myelodysplastic syndrome with ring sideroblasts","volume":"126","author":"Malcovati","year":"2015","journal-title":"Blood."},{"key":"B39","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.critrevonc.2018.07.013","article-title":"Prognostic value and clinical feature of SF3B1 mutations in myelodysplastic syndromes: a meta-analysis","volume":"133","author":"Tang","year":"2019","journal-title":"Crit Rev Oncol hematol."},{"key":"B40","doi-asserted-by":"publisher","first-page":"404","DOI":"10.1016\/j.ccell.2016.08.006","article-title":"Physiologic expression of Sf3b1(K700E) causes impaired erythropoiesis, aberrant splicing, and sensitivity to therapeutic spliceosome modulation","volume":"30","author":"Obeng","year":"2016","journal-title":"Cancer Cell."},{"key":"B41","doi-asserted-by":"publisher","first-page":"824","DOI":"10.1002\/ajh.25104","article-title":"Chronic myelomonocytic leukemia: 2018 update on diagnosis, risk stratification and management","volume":"93","author":"Patnaik","year":"2018","journal-title":"Am J Hematol."},{"key":"B42","doi-asserted-by":"publisher","first-page":"74","DOI":"10.1016\/j.blre.2018.07.004","article-title":"Current and evolving understanding of atypical chronic myeloid leukemia","volume":"33","author":"Schwartz","year":"2019","journal-title":"Blood Rev."},{"key":"B43","doi-asserted-by":"publisher","first-page":"2612","DOI":"10.1182\/blood-2011-02-333435","article-title":"CBL mutation in chronic myelomonocytic leukemia secondary to familial platelet disorder with propensity to develop acute myeloid leukemia (FPD\/AML)","volume":"119","author":"Shiba","year":"2012","journal-title":"Blood."},{"key":"B44","doi-asserted-by":"publisher","first-page":"2148","DOI":"10.1182\/blood-2016-06-724658","article-title":"Acquired expression of Cbl(Q367P) in mice induces dysplastic myelopoiesis mimicking chronic myelomonocytic leukemia","volume":"129","author":"Nakata","year":"2017","journal-title":"Blood."},{"key":"B45","doi-asserted-by":"publisher","first-page":"2705","DOI":"10.1182\/blood-2014-06-582809","article-title":"TET2 mutations predict response to hypomethylating agents in myelodysplastic syndrome patients","volume":"124","author":"Bejar","year":"2014","journal-title":"Blood."},{"key":"B46","doi-asserted-by":"publisher","first-page":"1147","DOI":"10.1038\/leu.2011.71","article-title":"Impact of TET2 mutations on response rate to azacitidine in myelodysplastic syndromes and low blast count acute myeloid leukemias","volume":"25","author":"Itzykson","year":"2011","journal-title":"Leukemia."},{"key":"B47","doi-asserted-by":"publisher","first-page":"174","DOI":"10.1016\/j.ebiom.2018.04.018","article-title":"Prognostic Role of gene mutations in chronic myelomonocytic leukemia patients treated with hypomethylating agents","volume":"31","author":"Duchmann","year":"2018","journal-title":"EBioMedicine."},{"key":"B48","doi-asserted-by":"publisher","first-page":"18","DOI":"10.1038\/ng.2495","article-title":"Recurrent SETBP1 mutations in atypical chronic myeloid leukemia","volume":"45","author":"Piazza","year":"2013","journal-title":"Nat Genet."},{"key":"B49","doi-asserted-by":"publisher","first-page":"1852","DOI":"10.1038\/leu.2013.133","article-title":"SETBP1 mutations occur in 9% of MDS\/MPN and in 4% of MPN cases and are strongly associated with atypical CML, monosomy 7, isochromosome i(17)(q10), ASXL1 and CBL mutations","volume":"27","author":"Meggendorfer","year":"2013","journal-title":"Leukemia."},{"key":"B50","doi-asserted-by":"publisher","first-page":"1401","DOI":"10.1038\/leu.2013.35","article-title":"SETBP1 mutations in 658 patients with myelodysplastic syndromes, chronic myelomonocytic leukemia and secondary acute myeloid leukemias","volume":"27","author":"Damm","year":"2013","journal-title":"Leukemia."},{"key":"B51","doi-asserted-by":"publisher","first-page":"2645","DOI":"10.1182\/blood-2014-02-553800","article-title":"Atypical chronic myeloid leukemia is clinically distinct from unclassifiable myelodysplastic\/myeloproliferative neoplasms","volume":"123","author":"Wang","year":"2014","journal-title":"Blood."},{"key":"B52","doi-asserted-by":"publisher","first-page":"277","DOI":"10.1002\/ajh.24972","article-title":"A phase II trial of ruxolitinib in combination with azacytidine in myelodysplastic syndrome\/myeloproliferative neoplasms","volume":"93","author":"Assi","year":"2018","journal-title":"Am J Hematol."}],"container-title":["Frontiers in Oncology"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.579221\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,10,7]],"date-time":"2020-10-07T05:22:58Z","timestamp":1602048178000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/article\/10.3389\/fonc.2020.579221\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,10,7]]},"references-count":52,"alternative-id":["10.3389\/fonc.2020.579221"],"URL":"https:\/\/doi.org\/10.3389\/fonc.2020.579221","relation":{},"ISSN":["2234-943X"],"issn-type":[{"value":"2234-943X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2020,10,7]]},"article-number":"579221"}}